Search

Displaying results 1471 - 1480 of 4590 in total
  1. Drug

    Nalmefene

    go.drugbank.com/drugs/DB06230
    ApprovedInvestigationalWithdrawn

    [L40684] The nasal spray formulation of nalmefene was approved by the FDA in May 2023.[L46511] … It is used for complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.

  2. Drug

    Ivarmacitinib

    go.drugbank.com/drugs/DB16756
    Investigational

    Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022...

  3. Drug

    Amoxicillin

    go.drugbank.com/drugs/DB01060
    ApprovedInvestigationalVet approved

    [A190648] Amoxicillin has similar activity to [penicillin] and [ampicillin], but leads to higher serum concentrations than ampicillin.

    Mixtures: Amoxicillin/Clavulansäure Astro 500 mg/100 mg Pulver zur Herstellung einer Injektions- oder Infusionslösung, Amoxicillin/Clavulansäure Astro 1000 mg/200 mg Pulver zur Herstellung einer Injektions- oder InfusionslösungProducts: AMOXICILINA MK 125 MG/ 5 ML., AMOXICILINA MK 250 MG CAPSULAS
  4. Drug

    Zuclopenthixol

    go.drugbank.com/drugs/DB01624
    ApprovedInvestigational

    It is known that zuclopenthixol is metabolized by Cytochrome P450 2D6. Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States. … These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.

  5. Drug

    Haloprogin

    go.drugbank.com/drugs/DB00793
    ApprovedWithdrawn

    The mechanism of action is unknown, but it is thought to be via inhibition of oxygen uptake and disruption of yeast membrane structure and function. … Tinea infections are superficial fungal infections caused by three species of fungi collectively known as dermatophytes (Trichophyton, Microsporum and Epidermophyton).

  6. Drug

    Quizartinib

    go.drugbank.com/drugs/DB12874
    ApprovedInvestigational

    [A260641] Quizartinib was approved by the FDA in July 2023 and developed under the brand name VANFLYTA by Daiichi Sankyo. … positive results from the QuANTUM-First trial for FLT3-ITD positive AML, where quizartinib combined with standard cytarabine and anthracycline induction and standard cytarabine consolidation, followed by

  7. Drug

    Trimetazidine

    go.drugbank.com/drugs/DB09069
    ApprovedInvestigational

    [A233215] It is hypothesized that trimetazidine inhibits 3-ketoacyl coenzyme A thiolase, which decreases fatty acid oxidation but not glucose metabolism, preventing the acidic conditions that exacerbate … [A233255,A233260] Acidic conditions, caused by anaerobic metabolism and fatty acid oxidation, in response to myocardial ischemia, activate sodium-hydrogen and sodium-calcium antiport systems.

  8. Drug

    Gallamine triethiodide

    go.drugbank.com/drugs/DB00483
    ApprovedWithdrawn

    It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198) … The actions of gallamine triethiodide are similar to those of tubocurarine, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac

  9. Drug

    Emricasan

    go.drugbank.com/drugs/DB05408
    Investigational

    Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA. … It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.

  10. Drug

    Faropenem medoxomil

    go.drugbank.com/drugs/DB05659
    Investigational

    It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc.